Aseptic filling technology for allogeneic cell therapy

CEFO Co., Ltd. (located in Seoul and Kwangmyung, South Korea) has a vision of regenerative medicine using advanced cell and tissue technology. They use the AT-Closed Vial® technology and Crystal™ M1 Filling Station to support their Phase I and II clinical trials and enable further scalability for their off-the-shelf cell therapy product.


As part of the pipeline, CEFO Co. develops musculoskeletal cell therapy, targeting the osteonecrosis of the femoral head, a debilitating disease of the highest part of the thigh bone. This therapy is based on the allogeneic umbilical cord-derived osteoblastic cells, making it high-yield (more than 10,000 vials from a single donor) and available off-the-shelf.

Moreover, this cell therapy is injectable and, as the patient receive living cells, before it, the product shall be frozen (cryostored). Entering into the Phase I of the clinical trials, the team of CEFO Co. was looking for a GMP-compliant aseptic fill & finish technology that would allow further scaling-up, and satisfy the needs in low-temperature storage and user-friendly administration.


AT production_2

Project Summary

Established in 2011, CEFO Co., which stands for “Cell Engineering For Origin” develops targeted cell therapy to cure intractable human diseases. Their CF-M801, an allogenic osteoblastic cell therapy for osteonecrosis of the femoral head (ONFH), has been approved by MFDS (Ministry of Food and Drug Safety of Korea) for Phase I and finished cell transplantation for nine patients. There was no adverse effect and immune rejection of allogenic osteoblasts. CF-M801 will extend its application to osteoporotic fracture, and adjuvant therapy to interbody cage-based spinal fusion. Their next-generation NK cell-based-cancer immunotherapy (CEN-K) is in pre-clinical study.

The introduction of the AT-Closed Vial® technology, which started with the small batch filling process Crystal™ M1, allows for safe aseptic fill & finish of the cell therapy CF-M801 in Phase I.

The scalability of the filling technology can support the further clinical trials needs of this allogeneic therapy. The AT-Closed Vial® process and its design contribute to the safety of the cryogenic storage and the ease of the administration procedures in the hospital.

Hyun Sook Park


"The AT-Closed Vial® is the only solution that meets our needs. This technology enables us to enter the final stage of our project. Thanks to the fill & finish solution by Aseptic Technologies, CF-M801 (cell therapy for bone regeneration) was approved by MFDS (Ministry of Food and Drug Safety of Korea) for Phase I and finished clinical application for the off-the-shelf transplantation. I have known Aseptic Technologies for long time and admire the uniqueness of their products."

Case study_CEFO_quality test room_2

Figures and facts

Best choice for cryopreserved products

Ensuring the so-called “Container Closure Integrity” in cryogeic temperatures.

Fast-tracking compliance

Contributed to the authorization of the clinical trial of cell therapy in South Korea.

In operation since 2017

Supporting the development and GMP manufacturing of CEFO Co. Ltd.

Want to know more ?